Formononetin reverses established osteopenia in adult ovariectomized rats

Menopause

Volumn 19, Issue 8, 2012, Pages 856-863

  Tyagi, Abdul Malik ^a   Srivastava, Kamini ^a   Singh, Anuj Kumar ^a   Kumar, Avinash ^a   Changkija, Bendangla ^a   Pandey, Rashmi ^a   Lahiri, Shibani ^a   Nagar, Geet K ^a   Yadav, Dinesh Kumar ^a   Maurya, Rakesh ^a   Trivedi, Ritu ^a   Singh, Divya ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; FORMONONETIN; GUM ARABIC; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE STRUCTURE; BONE TURNOVER; COLLAGEN DEGRADATION; CONTROLLED STUDY; FEMALE; FEMUR; NONHUMAN; NUCLEOTIDE SEQUENCE; OSSIFICATION; OSTEOID; OSTEOLYSIS; OSTEOPENIA; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RAT; SHAM PROCEDURE; SPRAGUE DAWLEY RAT; STATISTICAL SIGNIFICANCE; TIBIA; TRABECULAR BONE;

ANIMALS; BONE DISEASES, METABOLIC; BONE REMODELING; FEMALE; FEMUR; ISOFLAVONES; OSTEOGENESIS; OSTEOPROTEGERIN; OVARIECTOMY; PEPTIDE FRAGMENTS; PHYTOESTROGENS; PROCOLLAGEN; RANK LIGAND; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TIBIA;

EID: 84864288055     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e31824f9306     Document Type: Article

References (34)

1. Ha H, Lee HY, Lee JH, et al. Formononetin prevents ovariectomyinduced bone loss in rats. Arch Pharm Res 2010;33:625-632.
2. Bitto A, Burnett BP, Polito F, et al. Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol. Br J Pharmacol 2008;155:896-905.
3. Tyagi AM, Srivastava K, Sharan K, Yadav D, Maurya R, Singh D. Daidzein prevents the increase in CD4CD28 null T cells and B lymphopoiesis in ovariectomized mice: a key mechanism for anti-osteoclastogenic effect. PLoS One 2011;6:e21216.
4. Uebelhart D, Frey D, Frey-Rindova P, Goerres G, Michel BA. Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium. Z Rheumatol 2003;62:512-517.
5. Kulak Junior J, Kulak CA, Taylor HS. SERMs in the prevention and treatment of postmenopausal osteoporosis: an update. Arq Bras Endocrinol Metabol 2010;54:200-205.
6. Arjmandi BH. The role of phytoestrogens in the prevention and treatment of osteoporosis in ovarian hormone deficiency. J Am Coll Nutr 2001;20(Suppl 5):398S-402S; discussion 17S-20S.
7. Ishimi Y, Miyaura C, Ohmura M, et al. Selective effects of genistein, a soybean isoflavone, on B-lymphopoiesis and bone loss caused by estrogen deficiency. Endocrinology 1999;140:1893-1900.
8. Sharan K, Siddiqui JA, Swarnkar G, Maurya R, Chattopadhyay N. Role of phytochemicals in the prevention of menopausal bone loss: evidence from in vitro and in vivo, human interventional and pharmacokinetic studies. Curr Med Chem 2009;16:1138-1157.
9. Somjen D, Katzburg S, Kohen F, Gayer B, Livne E. Daidzein but not other phytoestrogens preserves bone architecture in ovariectomized female rats in vivo. J Cell Biochem 2008;103:1826-1832.
10. Picherit C, Coxam V, Bennetau-Pelissero C, et al. Daidzein is more efficient than genistein in preventing ovariectomy-induced bone loss in rats. J Nutr 2000;130:1675-1681.
11. Diel P, Schulz T, Smolnikar K, Strunck E, Vollmer G, Michna H. Ability of xeno- and phytoestrogens to modulate expression of estrogen-sensitive genes in rat uterus: estrogenicity profiles and uterotropic activity. J Steroid Biochem Mol Biol 2000;73:1-10.
12. Selvaraj V, Zakroczymski MA, Naaz A, et al. Estrogenicity of the isoflavone metabolite equol on reproductive and non-reproductive organs in mice. Biol Reprod 2004;71:966-972.
13. Gautam AK, Bhargavan B, Tyagi AM, et al. Differential effects of formononetin and cladrin on osteoblast function, peak bone mass achievement and bioavailability in rats. J Nutr Biochem 2011;22:318-327.
14. Wu JH, Li Q, Wu MY, et al. Formononetin, an isoflavone, relaxes rat isolated aorta through endothelium-dependent and endotheliumindependent pathways. J Nutr Biochem 2010;21:613-620.
15. Maurya R, Yadav DK, Singh G, et al. Osteogenic activity of constituents from Butea monosperma. Bioorg Med Chem Lett 2009;19:610-613.
16. Picherit C, Bennetau-Pelissero C, Chanteranne B, et al. Soybean isoflavones dose-dependently reduce bone turnover but do not reverse established osteopenia in adult ovariectomized rats. J Nutr 2001;131:723-728.
17. Bass RJ. Synthesis of chromones by cyclization of 2-hydroxyphenyl ketones with boron trifluoridediethyl ether and methanesulphonyl chloride. J Chem Soc Chem Commun 1976:78-79.
18. Pandey R, Gautam AK, Biju B, et al. Total extract and standardized fraction from the 1 stem-bark of Butea monosperma have osteoprotective action: evidence for the non-estrogenic osteogenic effect of the standardized fraction. Menopause 2010;17:602-610.
19. Bhargavan B, Gautam AK, Singh D, et al. Methoxylated isoflavones, cajanin and isoformononetin, have non-estrogenic bone forming effect via differential mitogen activated protein kinase (MAPK) signaling. J Cell Biochem 2009;108:388-399.
20. Trivedi R, Kumar A, Gupta V, et al. Effects of Egb 761 on bone mineral density, bone microstructure, and osteoblast function: possible roles of quercetin and kaempferol. Mol Cell Endocrinol 2009;302:86-91.
21. Tyagi AM, Gautam AK, Kumar A, et al. Medicarpin inhibits osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized mice. Mol Cell Endocrinol 2010;325:101-109.
22. Hale LV, Galvin RJ, Risteli J, et al. PINP: a serum biomarker of bone formation in the rat. Bone 2007;40:1103-1109.
23. Singer FR, Eyre DR. Using biochemical markers of bone turnover in clinical practice. Cleveland clinic journal of medicine. 2008;75(10):739-750.
24. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008;473:139-146.
25. Somekawa Y, Chiguchi M, Ishibashi T, Aso T. Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women. Obstet Gynecol 2001;97:109-115.
26. Mei J, Yeung SS, Kung AW. High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women. J Clin Endocrinol Metab 2001;86:5217-5221.
27. Kritz-Silverstein D, Goodman-Gruen DL. Usual dietary isoflavone intake, bone mineral density, and bone metabolism in postmenopausal women. J Womens Health Gend Based Med 2002;11:69-78.
28. Setchell KD, Lydeking-Olsen E. Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies. Am J Clin Nutr 2003;78(Suppl 3):593S-609S.
29. Brandi ML. Microarchitecture, the key to bone quality. Rheumatology (Oxford) 2009;48(Suppl 4):iv3-iv8.
30. Cheng PT, Aye LM, Vieth R, Muller K. Estrogen dose required to maintain parathyroid hormone mediated bone gain in osteopenic ovariectomized rats is probably higher than in preventive treatment with estrogen. Bone 1995;17(4 Suppl):329S-334S.
31. Shahnazari M, Yao W, Wang B, et al. Differential maintenance of cortical and cancellous bone strength following discontinuation of boneactive agents. J Bone Miner Res 2011;26:569-581.
32. Turner RT, Evans GL, Lotinun S, Lapke PD, Iwaniec UT, Morey-Holton E. Dose-response effects of intermittent PTH on cancellous bone in hindlimb unloaded rats. J Bone Miner Res 2007;22:64-71.
33. Gittens SA, Wohl GR, Zernicke RF, Matyas JR, Morley P, Uludag H. Systemic bone formation with weekly PTH administration in ovariectomized rats. J Pharm Pharm Sci 2004;7:27-37.
34. Wronski TJ, Dann LM, Scott KS, Cintron M. Long-term effects of ovariectomy and aging on the rat skeleton. Calcif Tissue Int 1989;45:360-366.